Table 3.
Clinical indicators related to hepatitis B virus (HBV) infection among the 11 patients who were positive for only hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg).
| Patient | Gender, age (years) | HBV infection history (years) | CD4+ T lymphocyte count (cells/ul) | ARTa | ART regimen | ART duration | HBV DNA, IU/ml | Quantitative detection of HBsAg, IU/ml | Quantitative detection of HBeAg, s/co | ALTb (U/L) | ASTc (U/L) |
| 1 | M, 33 | 10 | 23 | N | N/Ad | N/A | 4.36×106 | >250 | 752.7 | 69 | 93 |
| 2 | F, 26 | 5 | 280 | Y | TDFe/3TCf/EFVg | 5 years | <20 | >250 | 438.45 | 12 | 24 |
| 3 | M, 39 | —h | 220 | N | N/A | N/A | <20 | 1.68 | 3.54 | 679 | 732 |
| 4 | M, 39 | — | 36 | N | N/A | N/A | 3.36×107 | >250 | 1840.69 | 17 | 58 |
| 5 | M, 51 | — | 57 | N | N/A | N/A | 2.33×104 | 11.09 | 1.02 | 30 | 30 |
| 6 | M, 32 | 3 | 2 | N | N/A | N/A | 6.57×105 | 353.1 | 1109.894 | 16 | 26 |
| 7 | M, 27 | — | 38 | N | N/A | N/A | 6.08×102 | 10.04 | 1.46 | 46 | 44 |
| 8 | M, 34 | 12 | 319 | Y | AZTi/3TC/Lpv/rj | 2 years | 7.74×105 | 11121 | 618.552 | 19 | 19 |
| 9 | M, 28 | — | 14 | N | N/A | N/A | 6.04×108 | >250 | 1678 | 17 | 38 |
| 10 | M, 31 | — | 9 | Y | TDF/3TC/EFV | 1 month | 3.07×105 | 40751 | 239.68 | 23 | 49 |
| 11 | F, 62 | 14 | 220 | Y | TDF/3TC/Lpv/r | 2 years | <20 | 1837 | 1558.827 | 22 | 22 |
aART: antiretroviral therapy.
bALT: alanine aminotransferase.
cAST: aspartate aminotransferase.
dN/A: not applicable.
eTDF: tenofovir disoproxil fumarate.
f3TC: lamivudine.
gEFV: efavirenz.
hNot available (These patients did not receive HBsAg testing before but were diagnosed with chronic HBV during the implementation period of this study).
iAZT: zidovudine.
jLpv/r: lopinavir/ritonavir.